mNGS outperforms microbiological tests to diagnose bloodstream infections – BGI Insight

The research published in the Journal of Infection investigated the use of metagenomic next-generation sequencing (mNGS) in diagnosing bloodstream infections (BSIs) for immunocompromised hematology patients. Hematology patients are highly susceptible to BSIs, which can have severe consequences such as septic shock, multiple-organ failure, disseminated intravascular coagulation, and even death. An accurate and quick microbiological diagnosis of BSI is therefore essential for the control of the infection.

Characteristics of 256 immunocompromised patients with suspected bloodstream infections view more 

Image Credit: BGI Genomics​​​​​​​

In the study, conducted between January 2019 and December 2020 at Tongji Hospital with the participation of BGI Genomics researcher Wenqian Zhang, peripheral blood samples were collected from 256 immunocompromised hematology patients suspected of BSI, and both mNGS and conventional microbiological tests (CMTs) were performed. BSI diagnosis was confirmed in 189 out of 256 patients (73.8%). The detection rate of mNGS was significantly higher than that of CMTs, with mNGS identifying 187 infection cases and CMTs identifying 81. Results indicate mNGS outperformed CMT in detecting bloodstream infections.

Bacteria were detected in 17 patients (6.6%), fungi in 15 patients (5.9%), rare pathogens in 4 patients (1.6%), and multiple species in 55 patients (21.5%).

Based on mNGS results, viral infection was the most frequent BSI, identified in 96 out of 256 patients (37.5%). The five most common causative viruses were CMV (31.3%), EBV (14.8%), HSV1 (11.7%), BK virus (11.7%) and HHV6B (9.4%).

The results also showed that it was more likely for patients who had undergone hematopoietic stem cell transplantation (HSCT), than those who had not, to be infected by BK virus and HHV6B.

Overall, the study highlights the potential of mNGS as a powerful tool for the rapid and accurate diagnosis of BSIs in immunocompromised hematology patients, allowing for timely and effective treatment.

About BGI Genomics

BGI Genomics, headquartered in Shenzhen China, is the world's leading integrated solutions provider of precision medicine. Our services cover over 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BGI Genomics. (2023, March 24). mNGS outperforms microbiological tests to diagnose bloodstream infections – BGI Insight. News-Medical. Retrieved on April 24, 2024 from https://www.news-medical.net/news/20230324/mNGS-outperforms-microbiological-tests-to-diagnose-bloodstream-infections-e28093-BGI-Insight.aspx.

  • MLA

    BGI Genomics. "mNGS outperforms microbiological tests to diagnose bloodstream infections – BGI Insight". News-Medical. 24 April 2024. <https://www.news-medical.net/news/20230324/mNGS-outperforms-microbiological-tests-to-diagnose-bloodstream-infections-e28093-BGI-Insight.aspx>.

  • Chicago

    BGI Genomics. "mNGS outperforms microbiological tests to diagnose bloodstream infections – BGI Insight". News-Medical. https://www.news-medical.net/news/20230324/mNGS-outperforms-microbiological-tests-to-diagnose-bloodstream-infections-e28093-BGI-Insight.aspx. (accessed April 24, 2024).

  • Harvard

    BGI Genomics. 2023. mNGS outperforms microbiological tests to diagnose bloodstream infections – BGI Insight. News-Medical, viewed 24 April 2024, https://www.news-medical.net/news/20230324/mNGS-outperforms-microbiological-tests-to-diagnose-bloodstream-infections-e28093-BGI-Insight.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The Applications of Non-Invasive Prenatal Testing (NIPT) - 10 Years of Experience